Details

Autor(en) / Beteiligte

• Schaapveld, Michael
• Aleman, Berthe M.P
• van Eggermond, Anna M
• Janus, Cécile P.M
• Krol, Augustinus D.G
• van der Maazen, Richard W.M
• Roesink, Judith
• Raemaekers, John M.M
• de Boer, Jan Paul
• Zijlstra, Josée M
• van Imhoff, Gustaaf W
• Petersen, Eefke J
• Poortmans, Philip M.P
• Beijert, Max
• Lybeert, Marnix L
• Mulder, Ina
• Visser, Otto
• Louwman, Marieke W.J
• Krul, Inge M
• Lugtenburg, Pieternella J
• van Leeuwen, Flora E

Titel

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Ist Teil von

• The New England journal of medicine, 2015-12, Vol.373 (26), p.2499-2511

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Despite efforts to reduce the incidence of second cancer, the risk was not lower among 5-year survivors of Hodgkin's lymphoma in the Netherlands treated between 1989 and 2000, a period when more limited radiation fields and doses were used, than in earlier periods. Since the late 1960s, when combination chemotherapy and high-energy radiation therapy were introduced for the treatment of Hodgkin’s lymphoma, survival has increased dramatically. Cure has come at a price, however, because the treatment of Hodgkin’s lymphoma has been shown to increase the risk of subsequent malignant neoplasms and other late effects considerably. 1 – 22 Although very high relative risks have been observed for leukemia (especially among patients who were treated with alkylating agents) and non-Hodgkin’s lymphoma (which was not previously associated with a particular type of therapy), second solid cancers, the occurrence of which is related primarily to radiation therapy, contribute . . .